Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

Gregory P. Bisson, Ritesh Ramchandani, Sachiko Miyahara, Rosie Mngqibisa, Mitch Matoga, McNeil Ngongondo, Wadzanai Samaneka, Lucy Koech, Kogieleum Naidoo, Mohammed Rassool, Fredrick Kirui, Peter Banda, Vidya Mave, Dileep Kadam, Paul Leger, German Henestroza, Yukari C Manabe, Jing Bao, Johnstone Kumwenda, Amita GuptaMina C. Hosseinipour

Research output: Contribution to journalArticle

Abstract

Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4+ T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4+ T-cell response and new opportunistic infections. Results: Of 850 enrolled, the median pre-ART CD4+ T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4+ T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4+ T-cell count and viral load for those who died (n=43) vs. survived were 26 vs. 56 cells/μl and-2.7 vs.-2.7log 10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4+ T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P=038). Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.

Original languageEnglish (US)
Pages (from-to)2217-2225
Number of pages9
JournalAIDS
Volume31
Issue number16
DOIs
StatePublished - Oct 23 2017

Fingerprint

HIV
Mortality
CD4 Lymphocyte Count
T-Lymphocytes
Therapeutics
Tuberculosis
Peptide Initiation Factors
Opportunistic Infections
Viral Load
Leukocyte Count
Proportional Hazards Models
Serum Albumin
Hemoglobins
Neutrophils
Infection
Population

Keywords

  • antiretroviral therapy
  • early mortality
  • HIV-1 Infection
  • isoniazid prophylaxis
  • opportunistic infections
  • tuberculosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Bisson, G. P., Ramchandani, R., Miyahara, S., Mngqibisa, R., Matoga, M., Ngongondo, M., ... Hosseinipour, M. C. (2017). Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS, 31(16), 2217-2225. https://doi.org/10.1097/QAD.0000000000001606

Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. / Bisson, Gregory P.; Ramchandani, Ritesh; Miyahara, Sachiko; Mngqibisa, Rosie; Matoga, Mitch; Ngongondo, McNeil; Samaneka, Wadzanai; Koech, Lucy; Naidoo, Kogieleum; Rassool, Mohammed; Kirui, Fredrick; Banda, Peter; Mave, Vidya; Kadam, Dileep; Leger, Paul; Henestroza, German; Manabe, Yukari C; Bao, Jing; Kumwenda, Johnstone; Gupta, Amita; Hosseinipour, Mina C.

In: AIDS, Vol. 31, No. 16, 23.10.2017, p. 2217-2225.

Research output: Contribution to journalArticle

Bisson, GP, Ramchandani, R, Miyahara, S, Mngqibisa, R, Matoga, M, Ngongondo, M, Samaneka, W, Koech, L, Naidoo, K, Rassool, M, Kirui, F, Banda, P, Mave, V, Kadam, D, Leger, P, Henestroza, G, Manabe, YC, Bao, J, Kumwenda, J, Gupta, A & Hosseinipour, MC 2017, 'Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults', AIDS, vol. 31, no. 16, pp. 2217-2225. https://doi.org/10.1097/QAD.0000000000001606
Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M et al. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017 Oct 23;31(16):2217-2225. https://doi.org/10.1097/QAD.0000000000001606
Bisson, Gregory P. ; Ramchandani, Ritesh ; Miyahara, Sachiko ; Mngqibisa, Rosie ; Matoga, Mitch ; Ngongondo, McNeil ; Samaneka, Wadzanai ; Koech, Lucy ; Naidoo, Kogieleum ; Rassool, Mohammed ; Kirui, Fredrick ; Banda, Peter ; Mave, Vidya ; Kadam, Dileep ; Leger, Paul ; Henestroza, German ; Manabe, Yukari C ; Bao, Jing ; Kumwenda, Johnstone ; Gupta, Amita ; Hosseinipour, Mina C. / Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. In: AIDS. 2017 ; Vol. 31, No. 16. pp. 2217-2225.
@article{1a0a48d3b70d4ea99dca856b7361917e,
title = "Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults",
abstract = "Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4+ T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4+ T-cell response and new opportunistic infections. Results: Of 850 enrolled, the median pre-ART CD4+ T-cell count was 18 cells/μl and 67 (7.9{\%}) died. Baseline risk factors for death included lymphadenopathy, lower CD4+ T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4+ T-cell count and viral load for those who died (n=43) vs. survived were 26 vs. 56 cells/μl and-2.7 vs.-2.7log 10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4+ T-cell count was associated with a 20{\%} increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P=038). Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.",
keywords = "antiretroviral therapy, early mortality, HIV-1 Infection, isoniazid prophylaxis, opportunistic infections, tuberculosis",
author = "Bisson, {Gregory P.} and Ritesh Ramchandani and Sachiko Miyahara and Rosie Mngqibisa and Mitch Matoga and McNeil Ngongondo and Wadzanai Samaneka and Lucy Koech and Kogieleum Naidoo and Mohammed Rassool and Fredrick Kirui and Peter Banda and Vidya Mave and Dileep Kadam and Paul Leger and German Henestroza and Manabe, {Yukari C} and Jing Bao and Johnstone Kumwenda and Amita Gupta and Hosseinipour, {Mina C.}",
year = "2017",
month = "10",
day = "23",
doi = "10.1097/QAD.0000000000001606",
language = "English (US)",
volume = "31",
pages = "2217--2225",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "16",

}

TY - JOUR

T1 - Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults

AU - Bisson, Gregory P.

AU - Ramchandani, Ritesh

AU - Miyahara, Sachiko

AU - Mngqibisa, Rosie

AU - Matoga, Mitch

AU - Ngongondo, McNeil

AU - Samaneka, Wadzanai

AU - Koech, Lucy

AU - Naidoo, Kogieleum

AU - Rassool, Mohammed

AU - Kirui, Fredrick

AU - Banda, Peter

AU - Mave, Vidya

AU - Kadam, Dileep

AU - Leger, Paul

AU - Henestroza, German

AU - Manabe, Yukari C

AU - Bao, Jing

AU - Kumwenda, Johnstone

AU - Gupta, Amita

AU - Hosseinipour, Mina C.

PY - 2017/10/23

Y1 - 2017/10/23

N2 - Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4+ T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4+ T-cell response and new opportunistic infections. Results: Of 850 enrolled, the median pre-ART CD4+ T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4+ T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4+ T-cell count and viral load for those who died (n=43) vs. survived were 26 vs. 56 cells/μl and-2.7 vs.-2.7log 10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4+ T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P=038). Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.

AB - Background: Many HIV-infected individuals present with advanced HIV disease. These patients are at high risk of death after antiretroviral therapy (ART) initiation, but risk factors for death in these patients are unclear. Methods: We used data from a multisite randomized trial comparing empiric vs. preventive tuberculosis therapy in HIV-infected adults initiating ART with CD4+ T-cell counts less than 50 cells/μl to evaluate risk factors for death within 48 weeks after ART initiation. Cox proportional hazards models were fit to evaluate characteristics present at baseline and at 4 weeks after ART initiation, including the week 4 CD4+ T-cell response and new opportunistic infections. Results: Of 850 enrolled, the median pre-ART CD4+ T-cell count was 18 cells/μl and 67 (7.9%) died. Baseline risk factors for death included lymphadenopathy, lower CD4+ T-cell count, lower serum albumin, high white blood cell count, elevated neutrophil percentage, and lower hemoglobin. Among 746 participants with data at week 4, the median changes in CD4+ T-cell count and viral load for those who died (n=43) vs. survived were 26 vs. 56 cells/μl and-2.7 vs.-2.7log 10 copies/ml, respectively. Each 20 cell/μl lower change in week 4 CD4+ T-cell count was associated with a 20% increased risk of post week-4 mortality (adjusted hazard ratio 1.20, 1.01-1.42, P=038). Conclusion: Evidence of active infection and suboptimal immunologic response during the first month of ART are associated with death in the first year after ART initiation in those with advanced HIV disease taking tuberculosis preventive therapy. Strategies to reduce early mortality in this population warrant further investigation.

KW - antiretroviral therapy

KW - early mortality

KW - HIV-1 Infection

KW - isoniazid prophylaxis

KW - opportunistic infections

KW - tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=85030762251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030762251&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000001606

DO - 10.1097/QAD.0000000000001606

M3 - Article

C2 - 28742529

AN - SCOPUS:85030762251

VL - 31

SP - 2217

EP - 2225

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 16

ER -